Discussion {#onco12174-sec-0001}
==========

Based on the potential efficacy of lapatinib in HER2 gastric tumors, this multi‐institutional phase II trial was designed to assess lapatinib, 5‐FU, and oxaliplatin in combination with radiation therapy for the neoadjuvant treatment of localized esophagogastric cancers in patients with no prior therapy for the disease. It was hypothesized that the pCR primary endpoint would be increased from 30%--50% in a study population of 30 patients. Twelve patients (median age 64 years; 67% male, 58% moderately differentiated, 83% esophageal, 100% HER2‐positive) received a median of 5.6 weeks of treatment (range: 1.1--8.4). Four patients underwent tumor resection, and one of the four patients (25%) had a pCR. However, the number of patients evaluated here was too low to make an accurate comparison with other studies. Response Evaluation Criteria in Solid Tumors response assessment was performed for three patients, of whom two (67%) had at least a partial response. The most common lapatinib‐related adverse events included nausea (67%) and diarrhea (58%). Enrollment was halted due to low accrual. Only 12 patients were accrued from February 2013 to December 2014, due partly to the low number of patients with HER2‐positive gastroesophageal junction tumors. Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy.

###### Summary of clinical activity

![](onco12174-tbl-0001){#nlm-graphic-1}

Abbreviations: CI, confidence interval; OS, overall survival; pCR, pathologic complete response; PFS, progression‐free survival; TTP, time to progression.

Trial Information {#onco12174-sec-1101}
=================

DiseaseEsophageal cancerStage of Disease/TreatmentNeoadjuvantPrior therapyNoneType of Study ‐ 1Phase IIType of Study ‐ 2Single armPrimary EndpointPathologic complete responseSecondary EndpointProgression‐free survivalSecondary EndpointTime to progressionSecondary EndpointOverall survivalSecondary EndpointToxicityInvestigator\'s AnalysisActive, but patient numbers too low for accurate comparison

Drug Information for Phase II Control Arm {#onco12174-sec-1121}
=========================================

Drug 1 Generic/Working nameLapatinibTrade nameTykerb/TyverbCompany nameGlaxoSmithKline (GSK)Drug typeSmall moleculeDrug classHER‐2/neuDose750 mg and 1,000 mg (2 dose levels in safety lead in) milligrams (mg) per square meter (m^2^)Routeoral (p.o.)Schedule of administrationContinuous p.o. dosing during radiation therapyDrug 2 Generic/Working name5‐fluorouracilTrade nameAdrucilCompany nameTevaDrug typeAntineoplastic/cytotoxicDrug classAntimetaboliteDose225 mg/m^2^ milligrams (mg) per square meter (m^2^)RouteContinuous intravenous infusionSchedule of administrationDays 1--42 during radiation therapyDrug 3 Generic/Working nameOxaliplatinTrade nameEloxatinCompany nameSanofiDrug typeAntineoplastic/cytotoxicDrug classPlatinum compoundDose85 mg/m^2^ milligrams (mg) per square meter (m^2^)RouteIV

Patient Characteristics for Phase II Control Arm {#onco12174-sec-1106}
================================================

Number of patients, male8Number of patients, female4StageNot collectedAgeMedian (range): 64 (42--74)Number of prior systemic therapiesMedian (range): 0Performance Status: ECOG0 --- 81 --- 42 ---3 ---unknown ---Cancer Types or Histologic SubtypesEsophageal adenocarcinoma: 10Gastroesophageal junction adenocarcinoma: 2 (17%)

Primary Assessment Method for Phase II Control Arm {#onco12174-sec-1361}
==================================================

Total Patient Population Number of patients screened12Number of patients enrolled12Number of patients evaluable for toxicity12Number of patients evaluated for efficacy12Evaluation methodPathologic response---primary assessmentResponse assessment OTHER*n* = 1 (8%)(Median) duration assessments PFS3.253 months, confidence interval (CI): 95%(Median) duration assessments TTP6.768 months, CI: 95%RECIST 1.1, Secondary Assessment Number of patients evaluated for efficacy3Evaluation methodRECIST 1.1Response assessment PR*n* = 2 (67%)Response assessment SD*n* = 1 (33%)

Adverse Events, Phase II Control Arm {#onco12174-sec-1161}
====================================

imageJohn Wiley & Sons, Ltd.[^1]

Assessment, Analysis, and Discussion {#onco12174-sec-1192}
====================================

CompletionStudy terminated before completionTerminated ReasonDid not fully accrueInvestigator\'s AssessmentActive, but patient numbers too low for accurate comparison

 {#onco12174-sec-0002}

Neoadjuvant chemoradiation therapy for patients with localized esophagogastric cancers has been the subject of much discussion and controversy, with conflicting results compared with surgery alone seen in previous randomized clinical trials \[[1](#onco12174-bib-0001){ref-type="ref"}\], \[[2](#onco12174-bib-0002){ref-type="ref"}\], \[[3](#onco12174-bib-0003){ref-type="ref"}\]. Pathologic complete response (pCR) rates after neoadjuvant chemoradiation therapy are in the 25% range \[[1](#onco12174-bib-0001){ref-type="ref"}\], \[[2](#onco12174-bib-0002){ref-type="ref"}\], \[[3](#onco12174-bib-0003){ref-type="ref"}\].

Approximately 22% of patients with gastric or gastroesophageal junction (GEJ) adenocarcinomas have tumors that are human epidermal growth factor receptor 2 (HER2)‐positive \[[4](#onco12174-bib-0004){ref-type="ref"}\]. The ToGA trial found that patients with HER2‐positive gastric/GEJ adenocarcinomas had a significant improvement in overall survival (11.1 months to 13.8 months) when trastuzumab was added to the chemotherapy. Response rate and progression‐free survival were improved (47% vs. 35% and 6.7 months vs. 5.5 months, respectively) \[5\].

Lapatinib is a tyrosine kinase inhibitor of EGFR and HER2. It is U.S. Food and Drug Administration approved in combination with capecitabine for first‐line treatment of HER2‐positive advanced or metastatic breast cancer. In vivo, lapatinib has shown antitumor activity in gastric cancer cell lines when combined with 5‐fluorouracil (5‐FU), cisplatin, oxaliplatin, or paclitaxel \[[6](#onco12174-bib-0006){ref-type="ref"}\], \[[7](#onco12174-bib-0007){ref-type="ref"}\]. A recent phase III trial to assess potential benefit of lapatinib in combination with chemotherapy for the first‐line treatment of HER2‐positive metastatic gastric cancer showed that while overall survival was not improved with the addition of lapatinib, the response rate was significantly higher in the lapatinib arm \[[8](#onco12174-bib-0008){ref-type="ref"}\]. Similarly, results of the TyTAN trial of paclitaxel with or without lapatinib as treatment for Asian patients with HER2‐positive gastric cancer did not show improvement in overall survival \[[9](#onco12174-bib-0009){ref-type="ref"}\].

Based on the potential efficacy of lapatinib in HER2 gastric tumors, we designed a multi‐institutional phase II trial of lapatinib, 5‐FU, and oxaliplatin in combination with radiation therapy for the neoadjuvant treatment of localized esophagogastric cancers in patients with no prior therapy for the disease. It was hypothesized that the pCR primary endpoint would be increased from 30%--50% in a study population of 30 patients. Twelve patients (median age 64 years; 67% male, 58% moderately differentiated, 83% esophageal, 100% HER2‐positive) received a median of 5.6 weeks of treatment (range: 1.1--8.4). Four patients underwent tumor resection and one of the four patients (25%) had a pCR, which was similar to the pCR rates of previously reported studies \[[1](#onco12174-bib-0001){ref-type="ref"}\], \[[2](#onco12174-bib-0002){ref-type="ref"}\], \[[3](#onco12174-bib-0003){ref-type="ref"}\]. However, the number of patients evaluated in the present study was too low to make an accurate comparison with other studies. Response Evaluation Criteria in Solid Tumors response assessment was performed for three patients, of which two (67%) had at least a partial response. The most common lapatinib‐related adverse events included nausea (67%) and diarrhea (58%).

Enrollment was halted due to low accrual. Only 12 patients were accrued from February 2013 to December 2014, due partly to the low number of patients with HER2‐positive gastroesophageal junction tumors. Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy.

Figures and Tables {#onco12174-sec-0225}
==================

![Progression‐free survival (*n* = 12).\
Abbreviations: CI, confidence interval; pct, percent; PFS, progression‐free survival.](onco12174-fig-0001){#onco12174-fig-0001}

![Time to progression (*n* = 12).\
Abbreviations: CI, confidence interval; pct, percent; TTP, time to progression.](onco12174-fig-0002){#onco12174-fig-0002}

![Overall survival (*n* = 12).\
Abbreviations: CI, confidence interval; NA, not applicable; OS, overall survival; pct, percent.](onco12174-fig-0003){#onco12174-fig-0003}

###### Patient characteristics (*n* = 12)
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Abbreviations: FISH, fluorescent in situ hybridization; GE, gastroesophageal; HER2, human epidermal growth receptor 2; IHC, immunohistochemistry.
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[^1]: Abbreviations: NC/NA, no change from baseline/no adverse event.
